Quick Details
- Whatsapp、telegram::86 158 8959 9129
- Email:frank88rawpowder@outlook.com
- Processing Time:-
- Port:-
- Supply Ability: -
- Brand Name:-
CagriSema, is a combination
of cagrilintide, a dual amylin
and calcitonin receptor agonist,
and semaglutide, a GLP-1
agonist. It is
injected once weekly and is being tested in type 2 diabetes and obesity.
Preliminary trial results found a greater weight loss compared to either medication alone. HbA1c was significantly
improved compared to cagrilintide alone and non-significantly better than semaglutide alone.[1][2] In
a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, making CagriSema comparable in efficacy to tirzepatide.[3][4] A
future trial sponsored by Novo Nordisk is comparing tirzepatide and CagriSema head-to-head.[5] As
of 2023, CagriSema is in a Phase III trial.[6]
